Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 June are set out below…
Pearce IP BioBlast® for the week ending 27 June 2025
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast® for the week ending 20 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 June are set out below…
Pearce IP BioBlast® for the week ending 13 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 June are set out below…
Pearce IP BioBlast® for the week ending 6 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 June are set out below…
Pearce IP BioBlast® for the fortnight ending 30 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 30 May are set out below…
Scanning for Justice: Hytera’s Radio Technology Appeal Falls on Deaf Ears
The Full Court of the Federal Court has delivered judgment in the proceedings between Motorola Solutions Inc (Motorola) and Hytera Communications Corporation Ltd (Hytera), in their ongoing…
Pearce IP BioBlast® for the week ending 16 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 May are set out below…
Pearce IP BioBlast® for the week ending 9 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 9 May are set out below…
Pearce IP BioBlast® for the week ending 2 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 2 May are set out below…
Pearce IP BioBlast® for the fortnight ending 25 April 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 25 April 2025 are set out below…
Pearce IP BioBlast® for the week ending 11 April 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 11 April 2025 are set out below…
Pearce IP BioBlast® for the week ending 4 April 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 4 April 2025 are set out below…
Pearce IP BioBlast® for the week ending 28 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 March 2025 are set out below…
Pearce IP BioBlast® for the week ending 21 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 March 2025 are set out below…
Pearce IP BioBlast® for the week ending 14 March 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 14 March 2025 are set out below…
The End of the Road: High Court refuses Bayer’s Rivaroxaban Patents Special Leave Application
Last year, we reported on Sandoz’ victory in its appeal regarding the validity of two of Bayer’s Australian Xarelto® (rivaroxaban) patents…